
News|Articles|August 1, 2009
FDA Pipeline preview, August 2009 (trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, velaglucerase alfa)
Recent FDA action (through August 2009) related to trazodone, casopitant, sertindole, alogliptin, bepotastine, trabectedin, and velaglucerase alfa
Advertisement
Complete response
Recommended for approval
Not recommended for approval
Priority review
Orphan drug designation
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
2
What IRA drug prices will mean for PBMs, health plans and patients
3
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
4
Biosimilar competition could surpass IRA-negotiated savings by year three
5





















































